Latest News and Press Releases
Want to stay updated on the latest news?
-
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
DISCO signs exclusive deal with Amgen to develop cancer therapies from its surfaceome platform; deal worth up to $618M plus royalties.
-
DISCO Pharmaceuticals appoints biotech leader Mark Manfredi as CEO and raises €36M to advance surfaceome-targeted ADC therapies for hard-to-treat tumors
-
Abalos to present preclinical data on ABX-001 and its potential to further intensify anti-tumoral effects when combined with bispecific T-cell engagers